Resistance mechanisms of trastuzumab and treatment strategies in patients with breast cancer
10.3760/cma.j.issn.1673-422X.2012.04.011
- VernacularTitle:乳腺癌患者对曲妥珠单抗的耐药机制与治疗策略
- Author:
Guoyu DING
;
Xiao LIU
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Drug resistance,neoplasm;
Trastuzumab;
Molecular targeted therapy
- From:
Journal of International Oncology
2012;39(4):274-277
- CountryChina
- Language:Chinese
-
Abstract:
In the treatment of human epidermal growth factor receptor 2 (Her-2) overexpressing breast cancer,some patients have drug resistance to trastuzumab.Potential mechanisms of resistance to trastuzumab include impaired access of trastuzumab to Her-2 ; alternative signaling from insulin-like growth factor-1 receptor (IGF-1R),hepatocyte growth factor receptor (HGFR) and so on; aberrant downstream signaling caused by loss of phosphatase and tensin homologs deleted from chromosome 10 (PTEN);phosphatidylinositol 3-kinase catalytic alpha polypeptide gene (PIK3CA) mutation; over-expression of heat shock protein 90 (HSP90) and CD44. Additionally,potential strategies for overcoming resistance to trastuzumab include using new targeted medicines,such as pertuzumab,lapatinib and trastuzumab-DM1.
